CN116655482A - 一类γ-氨基丁酸衍生物的制备方法 - Google Patents

一类γ-氨基丁酸衍生物的制备方法 Download PDF

Info

Publication number
CN116655482A
CN116655482A CN202310657447.5A CN202310657447A CN116655482A CN 116655482 A CN116655482 A CN 116655482A CN 202310657447 A CN202310657447 A CN 202310657447A CN 116655482 A CN116655482 A CN 116655482A
Authority
CN
China
Prior art keywords
nmr
cdcl
preparation
yield
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310657447.5A
Other languages
English (en)
Inventor
郑鹏程
王青云
吴树权
池永贵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN202310657447.5A priority Critical patent/CN116655482A/zh
Publication of CN116655482A publication Critical patent/CN116655482A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/12—Formation of amino and carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明公开了一类γ‑氨基丁酸衍生物的制备方法，其特征在于：反应式如下：

Description

一类γ-氨基丁酸衍生物的制备方法
技术领域
本发明涉及一种新的菲尼布特、巴氯芬及咯利普兰的合成方法。
背景技术
γ-aminobutyric acids(GABA)药物主要有咯利普兰(英文名：Rolipram)，菲尼布特(英文名：Phenibut)和巴氯芬(英文名：Baclofen)。以上三种药物都是γ-氨基丁酸衍生物，其中咯利普兰和菲尼布特是神经类药物，用于治疗哮喘、关节炎、亨廷顿氏(Huntington′s)病，阿尔茨海默症和多发性硬化症等，可以在大脑中更好地调节过度兴奋和焦虑。巴氯芬具有松弛骨骼肌的作用，主要用于缓解脊髓肿瘤、横贯型脊髓炎、脊髓外伤、运动神经元病、脑血管病、脑膜炎、颅脑外伤引起的骨骼肌痉挛。目前该类化合物的合成受到广泛关注，已经发展出多种合成方法，但其中多利用过渡金属做催化剂，价格昂贵，步骤复杂，且很多方法中应用到了定量的手性助剂。因此，开发该类化合物的新合成方法是十分必要的。
发明内容
本发明要解决的技术问题是：提供一种操作方法简单、底物易制得的γ-氨基丁酸衍生物的制备方法，以解决现有技术中存在的问题。
本发明的技术方案是：一类γ-氨基丁酸衍生物的制备方法，反应式如下：
，其中R为苯基对位上的H、Cl或为苯基间位上的烷氧基和对位上的羟基同时取代，R1为芳香族取代基。
具体包含以下步骤：(1)0℃-30℃，碱性条件下，式1所示的化合物与II所示的硫酚类化合物经氮杂环卡宾类催化剂反应生成式III所示的中间体；(2)在甲醇作溶剂的条件下，步骤(1)中所得III所示的中间体在硫酸的作用下进行反应，反应结束后得到甲酯类产物4；(3)步骤(2)中所得产物与硼氢化钠和氯化镍混合，溶于甲醇中，室温下反应得到5；(4)步骤(3)中5再经过盐酸水解的条件，得到产物：菲尼布特和巴氯芬。
所述的氮杂环卡宾类催化剂为
所述步骤(1)的碱性条件为K2CO3，Cs2CO3，Na2CO3，Et3N，DABCO，DMAP，DIPEA，Quinecldine或DABCO。
所述步骤(1)反应在有机溶剂条件下进行，所述有机溶剂为THF,DCM,EtOAc,MTBE,Toluene,Xylene。
本发明的有益效果：本发明方法操作简单，步骤少而明确，底物易制备，反应条件温和，产率高，立体选择性高，便于手性合成咯利普兰，菲尼布特和巴氯芬。
具体实施方式
通过下列实施例可以进一步说明本发明，实施例是为了说明而非限制本发明的。本领域的任何普通技术人员都能够理解这些实施例不以任何方式限制本发明，可以对其做适当的修改和数据变换而不违背本发明的实质和偏离本发明的范围。
除非另有说明，化学品均购自商业化产品并且不用经进一步纯化。薄层色谱分析(TLC)使用(HSGF 254)硅胶板。硅胶柱层析使用青岛海洋硅胶(200-300目)。TLC显色采用UV光(254nm)。1HNMR图谱使用Bruker 400核磁共振仪表征，1H NMR为400MHz,13C NMR为100MHz,以d-CDC13为溶剂。化学位移的单位是ppm,耦合常数的单位是Hz。
高效液相色谱图使用waters厂家的的高效液相色谱仪。
(1)制备手性氰基化合物的合成路线：
制备实施方法和条件如下：
分别称取0.10mmol氰基醛1、0.12mmol芳香族硫酚2、0.01mmol氮杂环卡宾催化剂，0.02mmol三乙烯二胺做碱，并加入100mg分子筛。加入配有磁力搅拌子的10mL Schlenk反应管中，加入2mL甲苯做溶剂，使反应体系充分混合均匀。于30℃水浴中充分搅拌反应11小时，TLC监测反应完毕后，将整个反应体系通过湿法上样，经过柱层析分离，使用石油醚:乙酸乙酯＝6:1的洗脱剂得到目标化合物，称量后计算相应的产率，化合物通过熔点仪，旋光仪，核磁共振仪NMR，高分辨质谱仪HRMS和高效液相色谱仪HPLC予以表征。
对合成的化合物实验表征如下：
S-(对甲苯基)(R)-3-氰基-3-苯基丙烷硫代酸酯
取代基R1为苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,83％yield,38.6mg,m.p.94-96℃.
[α]25 D ＝-15.1(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.45–7.36(m,5H),7.28–7.24(d,J＝1.07Hz,4H),4.42–4.36(t,J＝7.32Hz,1H),3.38–3.31(dd,J＝16.13,7.75Hz,1H),3.21–3.14(dd,J＝16.19,6.96Hz,1H),2.41–2.39(s,3H).
13C NMR(101MHz,CDCl3)δ193.9,140.4,134.5,134.1,130.3,129.4,128.7,127.5,122.9,119.6,47.9,33.1,21.4.
HRMS(ESI,m/z):Masscalcd.for C17H16NOS+[M+H]+,282.0947；found 282.0943.HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm), Rt1(major)＝36.2min,Rt2(minor)＝42.8min；95:5er.
S-(对甲苯基)(R)-3-氰基-3-(4甲基苯基)丙烷硫代酸酯
取代基R1为4-甲基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,85％yield,25.1mg m.p.99-101℃.
[α]25 D ＝-61.3(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.37–7.31(m,2H),7.25–7.20(s,4H),7.12–7.04(m,2H),4.39–4.32(t,J＝7.28Hz,1H),3.34–3.27(dd,J＝16.14,7.25Hz,1H),3.16–3.09(dd,J＝16.16,7.35Hz,1H),2.40–2.35(s,3H).
13C NMR(101MHz,CDCl3)δ193.8,163.9,161.5,140.5,134.4,130.3,129.9,129.9,129.4,129.3,122.7,119.4,116.5,116.2,47.8,32.3,21.4.
19F NMR(377MHz,CDCl3)δ-112.65.
HRMS(ESI,m/z):Mass calcd.for C18H17NNaOS+[M+H]+,318.0923；found 318.0927.HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm), Rt1(major)＝27.4min,Rt2(minor)＝30.1min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(4-甲氧基苯基)丙烷硫代酸酯
取代基R1为4-甲氧基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；White solid,92％yield,28.6mg.m.p.168-170℃.；
[α]25 D ＝-71.5(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.40–7.35(m,1H),7.26–7.20(s,4H),7.17–7.14(dt,J＝7.64,1.34Hz,1H),7.11–7.04(m,2H),4.40–4.34(t,J＝7.25Hz,1H),3.35–3.29(dd,J＝16.23,7.43Hz,1H),3.18–3.11(dd,J＝16.20,7.12Hz,1H),2.40–2.36(s,3H).
13C NMR(101MHz,CDCl3)δ194.0,159.7,140.3,134.4,130.3,128.7,126.0,122.9,119.8,114.6,55.4,48.1,32.3,21.4.
HRMS(ESI,m/z):Mass calcd.for C18H17NNaO2S+[M+Na]+,334.0872；found334.0872.
HPLC analysis (Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝44.2min,Rt2(minor)＝47.3min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(4叔丁基苯基)丙烷硫代酸酯
取代基R1为4-叔丁基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；White solid,85％yield,28.7mg,m.p.81-82℃.
[α]25 D ＝-37.0(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.45–7.41(d,J＝8.43Hz,2H),7.33–7.24(m,6H),4.39–4.34(dd,J＝8.06,6.67Hz,1H),3.37–3.30(dd,J＝16.23,8.09Hz,1H),3.19–3.13(dd,J＝16.23,6.66Hz,1H),2.42–2.39(s,3H),1.36–1.33(s,9H).
13C NMR(101MHz,CDCl3)δ194.0,151.8,140.3,134.5,131.0,130.3,127.1,126.3,122.9,119.7,47.9,34.7,32.6,31.3,21.4.
HRMS(ESI,m/z):Mass calcd.for C21H23NNaOS+[M+Na]+,360.1393；found360.1393.
HPLC analysis(Chiralcel OD-H；25℃,IPA/Hexane＝10/90,0.5mL/min,254nm),Rt1(major)＝44.4min,Rt2(minor)＝59.3min；97:3er.
S-(对甲苯基)(R)-3-氰基-3-(4氟苯基)丙烷硫代酸酯
取代基R1为4-叔丁基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow oil,84％yield,yield,26.6mg.
[α]25 D ＝-35.9(c＝0.5in CHCl3).
1H NMR(400MHz,CDCl3)δ7.37–7.31(m,2H),7.25–7.20(s,4H),7.12–7.04(m,2H),4.39–4.32(t,J＝7.28Hz,1H),3.34–3.27(dd,J＝16.14,7.25Hz,1H),3.16–3.09(dd,J＝16.16,7.35Hz,1H),2.40–2.35(s,3H).
13C NMR(101MHz,CDCl3)δ193.8,162.7(d,J＝248.46Hz),140.5,134.4,130.3,129.9(d,J＝3.51Hz),129.4(d,J＝8.37Hz),129.3,122.7,119.4,116.4(d,J＝22.02Hz),47.8,32.3,21.4.
19F NMR(377MHz,CDCl3)δ-112.65.
HRMS(ESI,m/z):Mass calcd.for C17H14FNNaOS+[M+Na]+,322.0672；found322.0668.
HPLC analysis(ChiralcelAD-H；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝41.8min,Rt2(minor)＝51.7min；92:8er.
S-(对甲苯基)(R)-3-氰基-3-(4氯苯基)丙烷硫代酸酯
取代基R1为4-氯苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Whitesolid,84％yield,26.5mg,m.p.104-106℃.
[α]25 D ＝-11.6(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.40–7.34(d,J＝8.55Hz,2H),7.32–7.28(d,J＝8.53Hz,2H),7.25–7.19(s,4H),4.39–4.31(t,J＝7.25Hz,1H),3.34–3.27(dd,J＝16.22,7.23Hz,1H),3.16–3.09(dd,J＝16.23,7.28Hz,1H),2.41–2.34(s,3H).
13C NMR(101MHz,CDCl3)δ193.7,140.5,134.8,134.4,132.6,130.3,129.5,128.9,122.7,119.2,47.7,32.4,21.4.
HRMS(ESI,m/z):Mass calcd.for C17H14ClNNaOS+[M+Na]+,338.0377；found338.0377.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝36.0min,Rt2(minor)＝45.6min；86:14er.
S-(对甲苯基)(R)-3-氰基-3-(4溴苯基)丙烷硫代酸酯取代基R1为4-溴苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow solid,88％yield,88％yield,31.7mg,m.p.94-96℃.
[α]25 D ＝-76.3(c＝0.5in CHCl3).
1H NMR(400MHz,CDCl3)δ7.58–7.53(d,J＝8.47Hz,2H),7.29–7.25(d,J＝2.87Hz,6H),4.39–4.33(t,J＝7.25Hz,1H),3.37–3.30(dd,J＝16.26,7.20Hz,1H),3.19–3.12(dd,J＝16.27,7.33Hz,1H),2.42–2.38(s,3H).
13C NMR(101MHz,CDCl3)δ193.7,140.5,134.4,133.1,132.5,130.3,129.2,122.9,122.6,119.1,47.6,32.5,21.4.
HRMS(ESI,m/z):Mass calcd.for C17H14BrNNaOS+[M+Na]+,381.9872；found381.9869.
HPLC analysis (Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝42.6min,Rt2(minor)＝52.7min；80:20er.
S-(对甲苯基)(R)-3-氰基-3-(4三氟甲基苯基)丙烷硫代丙酸酯
取代基R1为4-三氟甲基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow oil,72％yield,25.2mg.
[α]25 D ＝-12.1(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.45–7.41(d,J＝8.71Hz,2H),7.29–7.24(d,J＝11.22Hz,6H),4.44–4.39(t,J＝7.25Hz,1H),3.39–3.32(dd,J＝16.28,7.32Hz,1H),3.21–3.15(dd,J＝16.26,7.26Hz,1H),2.43–2.39(s,3H).
13C NMR(101MHz,CDCl3)δ193.8,149.3(q,J＝1.94Hz),140.5,134.4,132.8,130.3,129.2,120.4(q,J＝257.84Hz),122.6,121.8,119.2,47.6,32.4,21.4.
19F NMR(377MHz,CDCl3)δ-57.87.
HRMS(ESI,m/z):Mass calcd.for C18H14F3NNaOS+[M+Na]+,372.0640；found372.0639.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝29.8min,Rt2(minor)＝36.5min；77:23er.
S-(对甲苯基)(R)-3-氰基-3-(3甲氧基苯基)丙烷硫代酸酯
取代基R1为3-甲氧基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；White solid,91％yield,28.3mg,m.p.107-108℃.
[α]25 D ＝-21.0(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.32–7.20(m,5H),6.96–6.85(m,3H),4.36–4.29(dd,J＝7.90,6.76Hz,1H),3.83–3.79(s,3H),3.33–3.26(dd,J＝16.13,7.88Hz,1H),3.17–3.10(dd,J＝16.14,6.79Hz,1H),2.39–2.35(s,3H).
13C NMR(101MHz,CDCl3)δ193.9,160.2,140.4,135.5,134.5,130.4,130.3,122.9,119.6,119.5,114.2,113.1,55.4,47.9,33.1,21.4.
HRMS(ESI,m/z):Mass calcd.for C18H17NNaO2S+[M+Na]+,334.0872；found334.0868.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝10/90,0.6mL/min,254nm),Rt1(major)＝29.2min,Rt2(minor)＝31.2min；95:5er.
S-(对甲苯基)(R)-3-氰基-3-(3氟苯基)丙烷硫代酸酯
取代基R1为3-氟苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowoil,85％yield,25.4mg.
[α]25 D ＝-26.5(c＝0.8in CHCl3).
1H NMR(400MHz,CDCl3)δ7.40–7.35(m,1H),7.26–7.20(s,4H),7.17–7.14(dt,J＝7.64,1.34Hz,1H),7.11–7.04(m,2H),4.40–4.34(t,J＝7.25Hz,1H),3.35–3.29(dd,J＝16.23,7.43Hz,1H),3.18–3.11(dd,J＝16.20,7.12Hz,1H),2.40–2.36(s,3H).
13C NMR(101MHz,CDCl3)δ193.7,163.0(d,J＝244.42Hz),140.5,136.4(d,J＝7.52Hz),134.4,131.0(d,J＝8.34Hz),130.3,123.2(d,J＝2.99Hz),122.7,119.0,115.8(d,J＝20.87Hz),114.8(d,J＝22.92Hz).47.6,32.7,21.4.
19F NMR(377MHz,CDCl3)δ-110.93.
HRMS(ESI,m/z):Mass calcd.for C17H14FNNaOS+[M+Na]+,322.0672；found322.0671.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝39.2min,Rt2(minor)＝45.6min；92:8er.
S-(对甲苯基)(R)-3-氰基-3-(3氯苯基)丙烷硫代酸酯
取代基R1为3-氯苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,85％yield,28.6mg,m.p.99-101℃.
[α]25 D ＝-9.8(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.41–7.32(m,3H),7.30–7.24(m,5H),4.40–4.34(t,J＝7.28Hz,1H),3.37–3.30(dd,J＝16.23,7.44Hz,1H),3.20–3.13(dd,J＝16.25,7.13Hz,1H),2.42–2.38(s,3H).
13C NMR(101MHz,CDCl3)δ193.7,140.5,136.0,135.2,134.5,130.6,130.3,129.0,127.8,125.7,122.7,119.0,47.6,32.7,21.4.
HRMS(ESI,m/z):Mass calcd.for C17H14ClNNaOS+[M+Na]+,338.0377；found338.0369.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝36.0min,Rt2(minor)＝45.6min；86:14er.
S-(对甲苯基)(R)-3-氰基-3-(2氟苯基)丙烷硫代酸酯
取代基R1为2-氟苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowoil,93％yield,27.8mg.
[α]25 D ＝-42.6(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.48–7.43(td,J＝7.64,1.76Hz,1H),7.39–7.33(m,1H),7.26–7.16(m,5H),7.14–7.08(m,1H),4.59–4.54(dd,J＝8.23,6.15Hz,1H),3.34–3.28(dd,J＝16.33,8.21Hz,1H),3.24–3.17(dd,J＝16.33,6.18Hz,1H),2.38–2.36(s,3H).
13C NMR(101MHz,CDCl3)δ193.5,160.0(d,J＝248.66Hz),140.4,134.5,130.8(d,J＝8.33Hz),130.3,129.5(d,J＝3.06Hz),125.0(d,J＝3.64Hz),122.8,121.3(d,J＝13.74Hz),118.5,116.2(d,J＝21.03Hz),45.8,27.6,21.4.
19F NMR(377MHz,CDCl3)δ-116.94.
HRMS(ESI,m/z):Mass calcd.for C17H14FNNaOS+[M+Na]+,322.0672；found322.0668.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝48.8min,Rt2(minor)＝65.7min；91:9er.
S-(对甲苯基)(R)-3-氰基-3-(2甲基苯基)硫代丙酸酯
取代基R1为2-甲基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Whitesolid,88％yield,27.4mg,m.p.108-109℃.
[α]25 D ＝-31.8(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.41–7.36(dd,J＝7.60,1.68Hz,1H),7.35–7.29(ddd,J＝8.16,7.49,1.71Hz,1H),7.28–7.25(s,1H),7.23–7.18(d,J＝8.20Hz,2H),7.00–6.94(td,J＝7.52,1.11Hz,1H),6.93–6.88(dd,J＝8.32,1.11Hz,1H),4.65–4.51(dd,J＝8.28,6.03Hz,1H),3.90–3.85(s,3H),3.28–3.16(m,2H),2.38–2.33(s,3H).
13C NMR(101MHz,CDCl3)δ194.2,156.3,140.1,134.5,130.2,130.1,129.0,123.2,122.1,121.1,119.6,111.0,55.6,45.5,28.5,21.4.
HRMS(ESI,m/z):Mass calcd.for C18H17NNaO2S+[M+Na]+,334.0872；found334.0884.
HPLC analysis(Chiralcel OD-H；25℃,IPA/Hexane＝15/85,0.6mL/min,254nm),Rt1(major)＝49.2min,Rt2(minor)＝79.0min；90:10er.
S-(对甲苯基)(R)-3-氰基-3-(3,5-(二甲基)苯基)硫代丙酸酯
取代基R1为3,5-二甲基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow solid,82％yield,25.4mg,m.p.103-104℃.
[α]25 D ＝-37.1(c＝0.8in CHCl3).
1H NMR(400MHz,CDCl3)δ7.27–7.21(m,4H),7.03–6.89(d,J＝7.29Hz,3H),4.31–4.23(dd,J＝8.04,6.65Hz,1H),3.32–3.24(dd,J＝16.08,8.06Hz,1H),3.14–3.07(dd,J＝16.07,6.64Hz,1H),2.40–2.36(s,3H),2.35–2.29(s,6H).
13C NMR(101MHz,CDCl3)δ194.0,140.3,139.1,134.5,134.0,130.2,125.2,123.0,119.8,48.0,33.0,21.4,21.3.
HRMS(ESI,m/z):Mass calcd.for C19H19NNaOS+[M+Na]+,332.1080；found332.1078.
HPLC analysis(Chiralcel IF；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝35.7min,Rt2(minor)＝43.2min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(3,4,-(二甲氧基)苯基)硫代丙酸酯
取代基R1为3,4-二甲氧基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow solid,90％yield,30.7mg,m.p.121-122℃.
[α]25 D ＝-23.1(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.28–7.23(d,J＝1.08Hz,4H),6.95–6.83(m,3H),4.37–4.31(t,J＝7.35Hz,1H),3.93–3.88(d,J＝1.72Hz,6H),3.35–3.28(dd,J＝16.03,7.51Hz,1H),3.19–3.12(dd,J＝16.07,7.17Hz,1H),2.42–2.37(s,3H).
13C NMR(101MHz,CDCl3)δ194.0,149.4,149.2,140.4,134.4,130.3,126.4,122.9,119.8,119.8,111.5,110.3,56.0,56.0,48.0,32.7,21.4.
HRMS(ESI,m/z):Mass calcd.for C19H19NNaO3S+[M+Na]+,364.0978；found364.0980.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝70.8min,Rt2(minor)＝77.4min；97:3er.
S-(对甲苯基)(R)-3-氰基-3-(胡椒基)硫代丙酸酯
取代基R1为胡椒基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,86％yield,28.0mg,m.p.125-127℃.
[α]25 D ＝-36.0(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.26–7.20(m,4H),6.88–6.70(m,3H),6.01–5.97(s,2H),4.31–4.24(t,J＝7.31Hz,1H),3.31–3.24(dd,J＝16.13,7.38Hz,1H),3.14–3.07(dd,J＝16.14,7.23Hz,1H),2.40–2.35(s,3H).
13C NMR(101MHz,CDCl3)δ193.9,148.4,147.9,140.4,134.4,130.3,127.6,122.9,121.1,119.6,108.8,107.8,101.6,48.0,32.8,21.4.
HRMS(ESI,m/z):Mass calcd.for C18H15NNaO3S+[M+Na]+,348.0665；found348.0664.
HPLCanalysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝87.9min,Rt2(minor)＝95.7min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(3-(环戊氧基)-4-甲氧基苯基)丙烷硫代丙酸酯取代基R1为3-(环戊氧基)-4-甲氧基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow solid,81％yield,32.0mg,m.p.107-108℃.
[α]25 D ＝-61.9(c＝0.4in CHCl3).
1H NMR(500MHz,CDCl3)δ7.26–7.16(s,4H),6.90–6.80(m,3H),4.80–4.73(tt,J＝6.30,3.04Hz,1H),4.33–4.25(t,J＝7.34Hz,1H),3.88–3.81(s,3H),3.32–3.24(dd,J＝16.00,7.42Hz,1H),3.16–3.08(dd,J＝16.04,7.26Hz,1H),2.43–2.35(s,3H),1.98–1.81(m,6H),1.64–1.57(m,2H).
13C NMR(101MHz,CDCl3)δ194.0,150.2,148.1,140.3,134.4,130.2,126.2,122.9,119.8,119.6,113.9,112.2,80.6,56.1,48.1,32.8,32.7,32.7,24.1,21.4.
HRMS(ESI,m/z):Mass calcd.for C23H25NNaO3S+[M+Na]+,418.1447；found418.1447.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝49.4min,Rt2(minor)＝40.0min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(3，4，5-三甲氧基苯基)丙烷硫代丙酸酯
取代基R1为3，4，5-三甲氧基苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow solid,94％yield,34.9mg,m.p.116-118℃.
[α]25 D ＝-184.3(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.29–7.24(d,J＝9.32Hz,4H),6.60–6.53(s,2H),4.36–4.30(t,J＝7.32Hz,1H),3.92–3.83(d,J＝8.20Hz,9H),3.37–3.29(dd,J＝16.08,7.67Hz,1H),3.21–3.13(dd,J＝16.06,7.01Hz,1H),2.43–2.37(s,3H).
13C NMR(101MHz,CDCl3)δ194.0,153.8,140.5,138.0,134.4,130.3,129.6,122.8,119.5,104.4,60.9,56.3,48.0,33.3,21.4.
HRMS(ESI,m/z):C20H21NNaO4S+[M+Na]+,394.1083；found 394.1092.
HPLC analysis(Chiralcel IB；25℃,IPA/Hexane＝10/90,0.8mL/min,254nm),Rt1(major)＝32.8min,Rt2(minor)＝53.6min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(1，1'-联苯基)丙烷硫代丙酸酯/>
取代基R1为1，1'-联苯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow solid,92％yield,32.9mg,m.p.97-98℃.
[α]25 D ＝-46.3(c＝0.4in CHCl3).
1H NMR(500MHz,CDCl3)δ7.65–7.54(dd,J＝14.00,7.69Hz,4H),7.49–7.35(m,5H),7.28–7.21(m,5H),4.45–4.38(t,J＝7.29Hz,1H),3.39–3.32(dd,J＝16.19,7.62Hz,1H),3.23–3.16(dd,J＝16.23,6.99Hz,1H),2.42–2.33(s,3H).
13C NMR(101MHz,CDCl3)δ193.9,141.7,140.4,140.1,134.5,133.0,130.3,128.9,128.0,127.9,127.8,127.1,122.9,119.5,47.9,32.7,21.4.
HRMS(ESI,m/z):Mass calcd.for C23H19NNaOS+[M+Na]+,380.1080；found380.1074.
HPLC analysis(Chiralcel OD-H；25℃,IPA/Hexane＝20/80,0.6mL/min,254nm),Rt1(major)＝31.5min,Rt2(minor)＝47.8min；96:4er
S-(对甲苯基)(R)-3-氰基-3-(1萘基)丙烷硫代丙酸酯
取代基R1为1-萘基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,90％yield,29.7mg,m.p.84-85℃.
[α]25 D ＝-16.3(c＝0.4in CHCl3).
1H NMR(500MHz,CDCl3)δ7.97–7.84(m,3H),7.75–7.69(d,J＝6.12Hz,1H),7.63–7.48(m,3H),7.28–7.22(q,J＝8.48,8.08Hz,4H),5.16–5.08(dd,J＝9.23,4.97Hz,1H),3.46–3.38(dd,J＝16.26,9.25Hz,1H),3.32–3.24(dd,J＝16.31,4.99Hz,1H),2.44–2.34(s,3H).
13C NMR(101MHz,CDCl3)δ194.2,140.4,134.5,134.1,130.3,129.7,129.6,129.5,127.4,126.4,126.0,125.5,122.9,121.9,119.6,47.1,30.3,21.4.
HRMS(ESI,m/z):Mass calcd.for C21H17NNaOS+[M+Na]+,354.0923；found354.0917.
HPLC analysis (Chiralcel IG； 25 ℃, IPA/Hexane ＝ 10/90, 0.6 mL/min,254 nm), Rt1 (major)＝61.9min,Rt2(minor)＝67.1min；94:6er.
S-(对甲苯基)(R)-3-氰基-3-(1-甲基-吲哚基)丙烷硫代丙酸酯
取代基R1为1-甲基-吲哚基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Brown solid,86％yield,28.8mg,m.p.127-128℃.
[α]25 D ＝-90.5(c＝0.4in CHCl3).
1H NMR(500MHz,CDCl3)δ7.65–7.59(d,J＝8.00Hz,1H),7.35–7.26(m,2H),7.24–7.15(m,5H),7.12–7.07(d,J＝0.60Hz,1H),4.66–4.58(ddd,J＝7.54,6.75,0.68Hz,1H),3.78–3.73(s,3H),3.38–3.25(m,2H),2.38–2.34(s,3H).
13C NMR(101MHz,CDCl3)δ194.3,140.2,137.3,134.5,130.2,127.5,125.4,123.2,122.5,120.0,119.8,118.5,109.9,107.2,46.9,32.9,24.9,21.4.
HRMS(ESI,m/z):Mass calcd.for C20H18N2NaOS+[M+Na]+,357.1032；found357.1031.
HPLC analysis(Chiralcel AS-H；25℃,IPA/Hexane＝30/70,0.6mL/min,254nm),Rt1(major)＝50.4min,Rt2(minor)＝58.2min；96:4er.
S-(对甲苯基)(R)-3-氰基-3-(1-噻吩)丙烷硫代丙酸酯取代基R1为1-噻吩,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellow oil,83％yield,23.9mg.
[α]25 D ＝-8.7(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.31–7.22(m,5H),7.12–7.08(dt,J＝3.56,1.07Hz,1H),7.01–6.96(dd,J＝5.17,3.56Hz,1H),4.70–4.62(td,J＝7.25,0.83Hz,1H),3.39–3.33(dd,J＝16.25,7.35Hz,1H),3.27–3.21(dd,J＝16.25,7.13Hz,1H),2.39–2.37(s,3H).
13C NMR(101MHz,CDCl3)δ193.5,140.4,135.8,134.4,130.3,127.3,127.0,126.2,122.8,118.7,48.0,28.3,21.4.
HRMS(ESI,m/z):Mass calcd.for C15H13NNaOS2 +[M+Na]+,310.0331；found310.0330.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝42.9min,Rt2(minor)＝46.3min；75:25er.
S-(对甲苯基)(R)-3-氰基-3-(1-环己烯基)丙烷硫代丙酸酯取代基R1为1-环己烯基,R2为4-甲基苯基，制备实施方法和条件同实施例I；Yellowsoild,47％yield,13.4mg,m.p.68-70℃.
[α]25 D ＝-11.4(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.33–7.18(m,4H),5.89–5.75(d,J＝1.08Hz,1H),3.74–3.60(t,J＝7.40Hz,1H),3.08–2.95(m,2H),2.44–2.33(s,3H),2.14–1.97(m,4H),1.73–1.66(t,J＝6.05Hz,2H),1.59–1.56(t,J＝1.73Hz,2H).
13C NMR(101MHz,CDCl3)δ194.1,140.3,134.4,130.2,130.0,127.8,123.1,119.3,44.2,35.0,25.9,25.2,22.4,21.7,21.4.
HRMS(ESI,m/z):Mass calcd.for C17H19NNaOS+[M+Na]+,308.1080；found308.1078.
HPLC analysis(Chiralcel AS3RCD；25℃,Ammonium bicarbonate/Acetonitrile＝30/70,0.6mL/min,254nm),Rt1(major)＝7.8min,Rt2(minor)＝7.0min；80:20er.
S-(4-甲氧基苯基)(R)-3-氰基-3-苯基硫代丙酸酯
取代基R1为苯基,R2为4-甲氧基苯基，制备实施方法和条件同实施例I；Yellowsolid,88％yield,26.2mg,m.p.112-114℃.
[α]25 D ＝-46.6(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.45–7.36(m,5H),7.30–7.27(m,2H),6.99–6.93(d,J＝8.78Hz,2H),4.42–4.36(t,J＝7.35Hz,1H),3.87–3.83(s,3H),3.37–3.30(dd,J＝16.15,7.77Hz,1H),3.19–3.13(dd,J＝16.16,6.93Hz,1H).
13C NMR(101MHz,CDCl3)δ194.5,161.0,136.1,134.1,129.4,128.7,127.5,119.6,117.0,115.1,55.4,47.8,33.1.
HRMS(ESI,m/z):Mass calcd.for C17H16NO2S+[M+Na]+,298.0896；found298.0902.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝57.9min,Rt2(minor)＝67.7min；96:4er.
S-(4-氟苯基)(R)-3-氰基-3-苯基硫代丙酸酯取代基R1为苯基,R2为4-氟苯基，制备实施方法和条件同实施例I；Yellow solid,87％yield,24.8mg,m.p.83-84℃.
[α]25 D ＝-38.7(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.46–7.33(m,7H),7.18–7.11(m,2H),4.42–4.35(dd,J＝7.89,6.83Hz,1H),3.39–3.32(dd,J＝16.18,7.96Hz,1H),3.22–3.15(dd,J＝16.15,6.80Hz,1H).
13C NMR(101MHz,CDCl3)δ193.4,163.8(d,J＝251.05Hz),136.6(d,J＝8.72Hz),133.9,129.4,128.8,127.5,121.6(d,J＝3.50Hz),119.5,116.8(d,J＝3.50Hz),48.0,33.1.
19F NMR(377MHz,CDCl3)δ-110.05.
HRMS(ESI,m/z):Mass calcd.for C16H12FNNaOS+[M+Na]+,308.0516；found308.0515.
HPLC analysis (Chiralcel IA； 25 ℃, IPA/Hexane ＝ 05/95, 0.7 mL/min,254 nm), Rt1 (major)＝30.6min,Rt2(minor)＝35.6min；93:7er.
S-(3-甲基苯基)(R)-3-氰基-3-苯基硫代丙酸酯/>
取代基R1为苯基,R2为3-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,86％yield,24.2mg,m.p.95-97℃.
[α]25 D ＝-78.2(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.42–7.34(m,5H),7.32–7.27(t,J＝7.50Hz,1H),7.25–7.21(m,1H),7.21–7.12(m,2H),4.39–4.33(dd,J＝7.87,6.84Hz,1H),3.35–3.28(dd,J＝16.15,7.87Hz,1H),3.17–3.11(dd,J＝16.17,6.83Hz,1H),2.37–2.34(s,3H).
13C NMR(101MHz,CDCl3)δ193.6,139.4,135.0,134.1,131.5,130.8,129.4,129.2,128.7,127.5,126.0,119.5,48.0,33.1,21.3.
HRMS(ESI,m/z):Mass calcd.for C17H15NNaOS+[M+Na]+,304.0767；found304.0763.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝28.3min,Rt2(minor)＝34.6min；95:5er.
S-(2-甲基苯基)(R)-3-氰基-3-苯基硫代丙酸酯
取代基R1为苯基,R2为2-甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,81％yield,22.8mg,m.p.98-99℃.
[α]25 D ＝-10.6(c＝0.4in CHCl3).
1H NMR(400MHz,CDCl3)δ7.46–7.32(m,8H),7.27–7.22(m,1H),4.43–4.36(t,J＝7.43Hz,1H),3.39–3.33(dd,J＝15.95,7.71Hz,1H),3.23–3.17(dd,J＝15.93,7.20Hz,1H),2.30–2.23(s,3H).
13C NMR(101MHz,CDCl3)δ192.9,142.1,135.8,134.0,131.0,130.6,129.4,128.7,127.5,126.8,119.5,47.9,33.2,20.6.
HRMS(ESI,m/z):Mass calcd.for C17H15NNaOS+[M+Na]+,304.0767；found304.0766.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝27.7min,Rt2(minor)＝30.3min；94:6er.
S-(2-甲氧基苯基)(R)-3-氰基-3-苯基硫代丙烷酸酯
取代基R1为苯基,R2为2-甲氧基苯基，制备实施方法和条件同实施例I；Yellowsolid,74％yield,22.0mg,m.p.104-106℃.
[α]25 D ＝-41.1(c＝0.5in CHCl3).
1H NMR(400MHz,CDCl3)δ7.48–7.34(m,7H),7.04–6.97(m,2H),4.44–4.37(t,J＝7.32Hz,1H),3.86–3.83(s,3H),3.40–3.33(dd,J＝16.23,7.75Hz,1H),3.23–3.16(dd,J＝16.22,6.91Hz,1H).
13C NMR(101MHz,CDCl3)δ192.7,159.2,136.6,134.2,132.3,129.3,128.6,127.5,121.2,119.6,114.6,111.7,56.0,47.7,33.0.
HRMS(ESI,m/z):Mass calcd.for C17H15NNaO2S+[M+Na]+,320.0716；found320.0728.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝44.3min,Rt2(minor)＝51.2min；94:6er.
S-(2,6-二甲基苯基)(R)-3-氰基-3-苯基硫代丙酸酯
取代基R1为苯基,R2为2，6-二甲基苯基，制备实施方法和条件同实施例I；Yellowsolid,78％yield,23.0mg,m.p.88-90℃.
[α]25 D ＝-28.2(c＝0.8in CHCl3).
1H NMR(400MHz,CDCl3)δ7.46–7.36(m,5H),7.29–7.24(m,1H),7.21–7.13(d,J＝7.55Hz,2H),4.44–4.37(t,J＝7.49Hz,1H),3.39–3.33(dd,J＝15.78,7.55Hz,1H),3.26–3.19(dd,J＝15.79,7.39Hz,1H),2.44–2.10(s,6H).
13C NMR(101MHz,CDCl3)δ192.4,142.8,134.0,130.4,129.4,128.7,128.4,127.6,125.9,119.6,47.9,33.2,21.6.
HRMS(ESI,m/z):Mass calcd.for C18H17NNaOS+[M+Na]+,318.0923；found318.0929.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝42.7min,Rt2(minor)＝50.1min；94:6er.
S-(萘基)(R)-3-氰基-3-苯基硫代丙烷酸酯取代基R1为苯基,R2为萘基，制备实施方法和条件同实施例I；White solid,81％yield,25.7mg,m.p.104-105℃.
[α]25 D ＝-50.2(c＝0.8in CHCl3).
1H NMR(400MHz,CDCl3)δ7.94–7.84(m,4H),7.61–7.54(ddd,J＝7.10,4.65,1.75Hz,2H),7.46–7.38(q,J＝4.59,3.63Hz,6H),4.45–4.39(dd,J＝7.83,6.87Hz,1H),3.44–3.37(dd,J＝16.16,7.90Hz,1H),3.26–3.20(dd,J＝16.19,6.81Hz,1H).
13C NMR(101MHz,CDCl3)δ193.6,134.6,134.1,133.5,133.5,130.6,129.4,129.1,128.7,128.1,127.9,127.5,127.5,126.8,123.7,119.6,48.1,33.1.
HRMS(ESI,m/z):Mass calcd.for C20H15NNaOS+[M+Na]+,340.0767；found340.0768.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.6mL/min,254nm),Rt1(major)＝64.5min,Rt2(minor)＝71.9min；94:6er.
methyl(R)-3-cyano-3-(3-(cyclopentyloxy)-4-methoxyphenyl)propanoate(5)
Purificationby flash column chromatography on silica gel(petroleumether/ethyl acetate＝10/1).White solid,91％yield,2.51g,m.p.98-99℃.
1H NMR(400MHz,CDCl3)δ6.90–6.81(m,3H),4.81–4.74(tt,J＝6.39,3.12 Hz,1H),4.27–4.19(dd,J＝8.04,6.85 Hz,1H),3.86–3.81(s,3H),3.76–3.68(s,3H),3.04–2.96(dd,J＝16.51,8.10 Hz,1H),2.87–2.79(dd,J＝16.51,6.84 Hz,1H),1.98–1.80(m,6H),1.67–1.56(m,2H).
13C NMR(101MHz,CDCl3)δ169.8,150.1,148.1,126.6,120.2,119.5,113.8,112.2,80.6,56.1,52.3,40.0,32.8,32.8,32.7,24.1.
HRMS(ESI,m/z):Mass calcd.for C17H21NNaO4 +[M+Na]+,326.1363；found326.1364.
(R)-Rolipram(6)
Purificationby flash column chromatography on silica gel(Dichloromethane/Methanol＝20/1).white solid,86％yield,2.2g,m.p.133-134℃.
[α]25 D ＝-30.7(c＝0.6 in CHCl3).
1H NMR(400MHz,CDCl3)δ6.84–6.75(m,3H),6.69–6.50(s,1H),4.81–4.74(tt,J＝5.79,3.46Hz,1H),3.86–3.81(s,3H),3.79–3.73(ddd,J＝9.30,8.07,1.04Hz,1H),3.67–3.59(m,1H),3.42–3.35(dd,J＝9.47,7.35Hz,1H),2.75–2.67(dd,J＝16.89,8.90Hz,1H),2.51–2.44(dd,J＝16.88,8.94Hz,1H),1.95–1.81(m,6H),1.67–1.56(m,2H).
13C NMR(101MHz,CDCl3)δ177.9,149.2,147.9,134.6,118.8,113.9,112.2,80.6,56.2,49.8,40.0,38.2,32.8,24.0.
HRMS(ESI,m/z):Mass calcd.for C16H21NNaO3 +[M+Na]+,298.1414；found298.1415.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝18.1min,Rt2(minor)＝22.5min；95:5er.
methyl(R)-3-cyano-3-phenylpropanoate(7)
Purificationby flash column chromatography on silica gel(petroleumether/ethyl acetate＝5/1).White solid,87％yield,56.9mg,m.p.92-94℃.
[α]25 D ＝15.6(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.40–7.32(m,5H),4.32–4.26(dd,J＝8.39,6.52Hz,1H),3.70–3.67(s,3H),3.04–2.97(dd,J＝16.67,8.38Hz,1H),2.87–2.81(dd,J＝16.68,6.58Hz,1H).
13C NMR(101MHz,CDCl3)δ169.7,134.5,129.3,128.6,127.4,120.0,52.3,39.7,33.1.
HRMS(ESI,m/z):Mass calcd.for C11H11NNaO2 +[M+Na]+,212.0682；found212.0685.
HPLC analysis(ChiralcelAD-H；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝33.8min,Rt2(minor)＝37.2min；95:5er.
methyl(R)-3-(4-chlorophenyl)-3-cyanopropanoate(8)
Purificationby flash column chromatography on silica gel(petroleumether/ethyl acetate＝5/1).Yellow solid,90％yield,77.8mg,m.p.93-95℃.
[α]25 D ＝10.2(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ7.41–7.35(m,2H),7.34–7.29(m,2H),4.32–4.25(t,J＝7.41Hz,1H),3.75–3.69(s,3H),3.05–2.99(dd,J＝16.66,7.75Hz,1H),2.87–2.80(dd,J＝16.69,7.07Hz,1H).
13C NMR(101MHz,CDCl3)δ169.4,134.8,132.9,129.5,128.8,119.5,52.5,39.7,32.6.
HRMS(ESI,m/z):Mass calcd.for C11H10ClNNaO2 +[M+Na]+,246.0292；found246.0288.
HPLC analysis(Chiralcel AD-H；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝33.9min,Rt2(minor)＝40.1min；87:13er.
(2)手性氰基化合物的GABA衍生物合成研究：
得到目标化合物，称量后计算相应的产率，化合物通过熔点仪，旋光仪，核磁共振仪NMR，高分辨质谱仪HRMS和高效液相色谱仪HPLC予以表征。
由化合物3a和3f转化为化合物(R)-Phenibut和(R)-Baclofen的制备方法
在一个配有磁力搅拌子的100mL茄形瓶中加入3a(2.81g,10.0mmol)或3f(3.16g,10.0mmol)，加入30mL甲醇使其溶解，再加入2mL浓硫酸于室温下搅拌，TLC监测至反应完毕，将反应体系冷却到0℃，加水稀释并用乙酸乙酯萃取，利用无水硫酸钠干燥。旋干得到粗产品后，通过柱层析分离，洗脱剂极性石油醚:乙酸乙酯＝10:1得到目标化合物7和8，分别是87％和90％的收率。
在一个配有磁力搅拌子的50mL茄形瓶中加入化合物7(1.66g,8.68mmol)或8(2.00g,9.00mmol)并溶于20mL甲醇中，加入5.0equiv硼氢化钠(1.72g,45.00mmol)，在室温下搅拌一小时，TLC监测至反应完毕。利用饱和氯化铵溶液淬灭，经无水硫酸钠干燥，旋干得到粗产品后，通过柱层析分离，洗脱剂极性石油醚:乙酸乙酯＝5:1以85％和90％的收率得到相应的目标化合物，之后将化合物加入6NHCl中，在100℃条件下回流18小时，浓缩干燥后得到目标化合物(R)-菲尼布特(收率83％)和(R)-巴氯芬(收率79％)。
(R)菲尼布特
Purificationby flash column chromatography on silica gel(petroleumether/ethyl acetate＝5/1).White solid,83％yield,1.4g.
[α]25 D ＝-20.6(c＝0.6in H2O).
1H NMR(300MHz,D2O)d 2.65(dd,1H,J 15.8and 8.8Hz),2.75(dd,1H,J 15.8and5.3Hz),3.10-3.30(m,3H),7.26-7.36(m,5H).
13C NMR(75MHz,D2O)d 40.7,42.4,46.3,130.3,130.8,131.8,140.8,177.9.
HRMS(ESI,m/z):Mass calcd.For C10H14NO2 +[M+H]+,180.1019；found 180.1020.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝24.8min,Rt2(minor)＝28.0min；95:5er.
(R)巴氯芬
Purificationby flash column chromatography on silica gel(petroleumether/ethyl acetate＝5/1).White solid,79％yield,1.2g.
[α]25 D ＝-9.1(c＝0.6in H2O).
1H NMR(300MHz,D2O)d 2.73(dd,1H,J 16.4and 8.8Hz),2.86(dd,1H,J 16.4and5.9Hz),3.20-3.48(m,3H),7.33(d,2H,J 8.8Hz),7.43(d,2H,J 8.8Hz).
13C NMR(75MHz,D2O)d 38.4,39.6,43.8,129.4,129.6,133.5,137.1,175.5.
HRMS(ESI,m/z):Mass calcd.For C10H13ClNO2 +[M+H]+,214.0629；found214.0630.
HPLC analysis(Chiralcel AD-H；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝18.9min,Rt2(minor)＝20.2min；87:13er.
由化合物3q转化为化合物6的制备方法
在一个配有磁力搅拌子的100mL茄形瓶中加入3q(3.60g,13.5mmol)，加入30mL甲醇使其溶解，再加入2mL浓硫酸于室温下搅拌，TLC监测至反应完毕，将反应体系冷却到0℃，加水稀释并用乙酸乙酯萃取，利用无水硫酸钠干燥。旋干得到粗产品后，通过柱层析分离，洗脱剂极性石油醚:乙酸乙酯＝10:1以91％的收率得到目标化合物5。
在一个配有磁力搅拌子的50mL茄形瓶中加入化合物5(2.76g,8.25mmol)并溶于20mL甲醇中，加入5.0equiv硼氢化钠(1.56g,41.21mmol)，在室温下搅拌一小时，TLC监测至反应完毕。利用饱和氯化铵溶液淬灭，经无水硫酸钠干燥，旋干得到粗产品后，通过柱层析分离，洗脱剂极性石油醚:乙酸乙酯＝20:1以86％的收率得到目标化合物6。
(R)咯利普兰
white solid,86％yield,2.2g,m.p.133-134℃.
[α]25 D ＝-30.7(c＝0.6in CHCl3).
1H NMR(400MHz,CDCl3)δ6.84–6.75(m,3H),6.69–6.50(s,1H),4.81–4.74(tt,J＝5.79,3.46Hz,1H),3.86–3.81(s,3H),3.79–3.73(ddd,J＝9.30,8.07,1.04Hz,1H),3.67–3.59(m,1H),3.42–3.35(dd,J＝9.47,7.35Hz,1H),2.75–2.67(dd,J＝16.89,8.90Hz,1H),2.51–2.44(dd,J＝16.88,8.94Hz,1H),1.95–1.81(m,6H),1.67–1.56(m,2H).
HRMS(ESI,m/z):Mass calcd.for C16H21NNaO3 +[M+Na]+,298.1414；found298.1415.
HPLC analysis(Chiralcel IA；25℃,IPA/Hexane＝05/95,0.5mL/min,254nm),Rt1(major)＝18.1min,Rt2(minor)＝22.5min；95:5er.

Claims (5)

1.一类γ-氨基丁酸衍生物的制备方法，其特征在于：反应式如下：
，
其中R为苯基对位上的H、Cl或为苯基间位上的烷氧基和对位上的羟基同时取代，R1为芳香族取代基。
2.根据权利要求1所述的一类γ-氨基丁酸衍生物的制备方法，其特征在于：具体包含以下步骤：(1)0℃-30℃，碱性条件下，式1所示的化合物与II所示的硫酚类化合物经氮杂环卡宾类催化剂反应生成式III所示的中间体；(2)在甲醇作溶剂的条件下，步骤(1)中所得III所示的中间体在硫酸的作用下进行反应，反应结束后得到甲酯类产物4；(3)步骤(2)中所得产物与硼氢化钠和氯化镍混合，溶于甲醇中，室温下反应得到5；(4)步骤(3)中5再经过盐酸水解的条件，得到产物：菲尼布特和巴氯芬。
3.根据权利要求2所述的一类γ-氨基丁酸衍生物的制备方法，其特征在于：所述的氮杂环卡宾类催化剂为
4.根据权利要求2所述的一类γ-氨基丁酸衍生物的制备方法，其特征在于：所述步骤(1)的碱性条件为K2CO3，Cs2CO3，Na2CO3，Et3N，DABCO，DMAP，DIPEA，Quinecldine或DABCO。
5.根据权利要求2所述的一类γ-氨基丁酸衍生物的制备方法，其特征在于：所述步骤(1)反应在有机溶剂条件下进行，所述有机溶剂为THF,DCM,EtOAc,MTBE,Toluene,Xylene。
CN202310657447.5A 2023-06-05 2023-06-05 一类γ-氨基丁酸衍生物的制备方法 Pending CN116655482A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310657447.5A CN116655482A (zh) 2023-06-05 2023-06-05 一类γ-氨基丁酸衍生物的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310657447.5A CN116655482A (zh) 2023-06-05 2023-06-05 一类γ-氨基丁酸衍生物的制备方法

Publications (1)

Publication Number Publication Date
CN116655482A true CN116655482A (zh) 2023-08-29

Family

ID=87720328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310657447.5A Pending CN116655482A (zh) 2023-06-05 2023-06-05 一类γ-氨基丁酸衍生物的制备方法

Country Status (1)

Country Link
CN (1) CN116655482A (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2146246C1 (ru) * 1998-05-15 2000-03-10 Гареев Гегель Амирович СПОСОБ ПОЛУЧЕНИЯ ГИДРОХЛОРИДА γ-АМИНО-βФЕНИЛМАСЛЯНОЙ КИСЛОТЫ (ФЕНИБУТА)
US20120029230A1 (en) * 2010-07-27 2012-02-02 Jen-Huang Kuo Method for preparing chiral baclofen
CN102863347A (zh) * 2009-03-17 2013-01-09 孟坤 手性巴氯芬的制备方法
CN104557583A (zh) * 2015-02-02 2015-04-29 中山大学 一种合成γ-氨基丁酸类手性化合物的方法
CN112321475A (zh) * 2020-11-13 2021-02-05 四川大学 一种γ-氨基酸类似物及其合成方法
CN112479966A (zh) * 2020-12-11 2021-03-12 南京工业大学 一种咯利普兰的合成方法
WO2021161346A1 (en) * 2020-02-14 2021-08-19 Council Of Scientific And Industrial Research Process for the preparation of gamma amino butyric acids and analogs thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2146246C1 (ru) * 1998-05-15 2000-03-10 Гареев Гегель Амирович СПОСОБ ПОЛУЧЕНИЯ ГИДРОХЛОРИДА γ-АМИНО-βФЕНИЛМАСЛЯНОЙ КИСЛОТЫ (ФЕНИБУТА)
CN102863347A (zh) * 2009-03-17 2013-01-09 孟坤 手性巴氯芬的制备方法
US20120029230A1 (en) * 2010-07-27 2012-02-02 Jen-Huang Kuo Method for preparing chiral baclofen
CN104557583A (zh) * 2015-02-02 2015-04-29 中山大学 一种合成γ-氨基丁酸类手性化合物的方法
WO2021161346A1 (en) * 2020-02-14 2021-08-19 Council Of Scientific And Industrial Research Process for the preparation of gamma amino butyric acids and analogs thereof
CN112321475A (zh) * 2020-11-13 2021-02-05 四川大学 一种γ-氨基酸类似物及其合成方法
CN112479966A (zh) * 2020-12-11 2021-03-12 南京工业大学 一种咯利普兰的合成方法

Similar Documents

Publication Publication Date Title
US10442816B2 (en) Synthesis of substituted salicylaldehyde derivatives
CN111606820B (zh) N-碘苯-n-苯基酰胺类化合物的制备方法
CN116655482A (zh) 一类γ-氨基丁酸衍生物的制备方法
JP5108777B2 (ja) 軸不斉を有する光学活性な４級アンモニウム塩およびそれを用いたα−アミノ酸およびその誘導体の製造方法
CN113683573A (zh) 一种可见光催化苄基化喹喔啉酮化合物的制备方法
CN105820064A (zh) 一种联苯基丙氨醇衍生物的合成方法及中间体
Hon et al. An extremely efficient way to prepare conjugated carbonyl compounds from terminal alkenes via the reactions of ozonides, triethylamine and stable phosphorus ylides
Midura et al. Phosphonates containing sulfur and selenium. Synthesis of vinylphosphonates bearing α-sulfenyl, α-selenenyl, α-sulfinyl and α-seleninyl moieties and studies on nucleophilic addition
KR20040090062A (ko) 4-클로로-3-히드록시부탄산 에스테르의 제조방법
Shutske A new synthesis of 3-phenyl-1, 2-benzisoxazoles: sterically constrained 3-phenyl-1, 2-benzisoxazoles by intramolecular carbon: nitrogen bond formation at a hindered carbonyl group
JP4043330B2 (ja) 芳香族エーテル類の製造方法
JPH02190A (ja) 光学活性ホスフィン化合物
JP7400075B2 (ja) 手性β－アミノ酸及びその誘導体の消旋調製方法
WO1995009150A1 (en) Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
CN1714074A (zh) 芳族腈化合物的生产方法
KR100349035B1 (ko) 인듐 금속 및 산을 이용하여 알데히드(-ｃｈｏ)의 알릴화및 니트로기(-ｎｏ₂)의 환원 반응을 동시에 행하는 방법
Ruso et al. A unified approach for the synthesis of symmetrical and unsymmetrical dibenzyl ethers from aryl aldehydes through reductive etherification
CN114805069B (zh) 一种由末端烯烃合成α二氟代酯类衍生物的方法
SU1243625A3 (ru) Способ получени @ -функциональных фосфолов
CN111807942B (zh) 一种多取代茚酮衍生物的制备方法
CN113292555B (zh) 一种Tropifexor的制备方法
Garcı́a et al. Highly stereoselective hydrocyanation of optically pure α-sulfinylaldehydes
CN112679336A (zh) 一种异相钯金属催化合成苯丙酸类化合物的方法
CN113248410A (zh) 一种银介导的n-芳酰肼类化合物的制备方法
CN106045827A (zh) 一种芳基丙酮类化合物的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination